Strategic Blueprint
ABBV icon

Strategic Blueprint’s AbbVie ABBV Stock Holding History

Strategic Blueprint’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.42M Sell
9,268
-470
-5% -$120K 0.12% 177
2026
Q2 		$2.45M Buy
9,738
+261
+3% +$56.2K 0.12% 174
2026
Q1 		$2.06M Buy
9,477
+178
+2% +$39.5K 0.12% 173
2025
Q4 		$2.12M Sell
9,299
-992
-10% -$226K 0.13% 166
2025
Q3 		$2.38M Buy
10,291
+330
+3% +$67.2K 0.1% 183
2025
Q2 		$1.85M Sell
9,961
-42
-0.4% -$7.81K 0.09% 201
2025
Q1 		$2.1M Sell
10,003
-280
-3% -$54.4K 0.11% 170
2024
Q4 		$1.83M Buy
10,283
+179
+2% +$32.9K 0.11% 168
2024
Q3 		$2M Sell
10,104
-1,232
-11% -$230K 0.12% 151
2024
Q2 		$1.94M Buy
11,336
+200
+2% +$33.1K 0.13% 144
2024
Q1 		$2.03M Buy
11,136
+686
+7% +$118K 0.14% 145
2023
Q4 		$1.62M Sell
10,450
-856
-8% -$125K 0.13% 155
2023
Q3 		$1.69M Buy
11,306
+286
+3% +$42K 0.16% 140
2023
Q2 		$1.48M Buy
11,020
+72
+0.7% +$10.6K 0.14% 147
2023
Q1 		$1.74M Buy
10,948
+812
+8% +$124K 0.18% 129
2022
Q4 		$1.64M Buy
10,136
+177
+2% +$27.1K 0.19% 127
2022
Q3 		$1.34M Buy
9,959
+807
+9% +$116K 0.16% 141
2022
Q2 		$1.4M Buy
9,152
+207
+2% +$31.6K 0.17% 133
2022
Q1 		$1.45M Sell
8,945
-817
-8% -$119K 0.17% 128
2021
Q4 		$1.32M Buy
9,762
+1,352
+16% +$160K 0.17% 135
2021
Q3 		$907K Sell
8,410
-1,037
-11% -$118K 0.14% 150
2021
Q2 		$1.06M Buy
9,447
+1,239
+15% +$140K 0.17% 126
2021
Q1 		$888K Buy
8,208
+784
+11% +$83.9K 0.19% 118
2020
Q4 		$795K Buy
7,424
+547
+8% +$52.6K 0.2% 102
2020
Q3 		$602K Buy
+6,877
New +$647K 0.19% 101
2019
Q4 		– Sell
-1,735
Closed -$131K – 93
2019
Q3 		$131K Buy
+1,735
New +$119K 0.1% 86
2019
Q1 		– Sell
-11,255
Closed -$1.04M – 72
2018
Q4 		$1.04M Buy
+11,255
New +$990K 1.51% 22

Other funds holding ABBV

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $111B AUM 30.48% 1-Year Est. Return

Strategic Blueprint's ABBV Position: Q3 2026 in Review

Strategic Blueprint reduced its AbbVie (ABBV) stake by 4.8% in Q3 2026, selling an estimated $120K and leaving 9,268 shares worth $2.42M. The position accounts for 0.12% of the portfolio, ranked #177.

Strategic Blueprint first reported a position in ABBV in Q4 2018 and has held it in 27 quarters since. The position peaked at $2.45M in Q2 2026. 3,064 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Strategic Blueprint held 9,268 shares of AbbVie worth $2.42M as of Q3 2026.
  • Strategic Blueprint sold 470 AbbVie shares in Q3 2026, an estimated $120K.
  • AbbVie made up 0.12% of Strategic Blueprint's portfolio in Q3 2026, its #177 holding.
  • Strategic Blueprint first reported a position in AbbVie in Q4 2018 and has held it in 27 quarters since.
  • Strategic Blueprint's AbbVie position peaked at $2.45M in Q2 2026.
  • 3,064 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Strategic Blueprint's 13F filing for Q3 2026, filed 22 Oct 2026.